AusperBio adds $120M series C to push hep B drug through ph. 3
AusperBio secures $120M in Series C financing to advance its hepatitis B therapeutic candidate into Phase 3 clinical trials.
AusperBio
Private
Clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic hepatitis B virus (HBV) infection. Raised $120M Series C to advance its lead HBV drug candidate through Phase 3 clinical trials.
Company Info
Sector:Antiviral Therapeutics
Headquarters:Northern California, USA
Founded:2018
Website:ausperbio.com/
Funding Round:Series C
Total Funding:$120M
Upcoming Milestones & Key Dates
2027
Clinical Readout
Phase 3 data readout expected